Obicetrapib vs Obicetrapib/ezetimibe (Evlarco)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: CETP · full Atherosclerotic Cardiovascular Disease pipeline

Obicetrapib

Marketed by A. Menarini under a licence from NewAmsterdam Pharma

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
Partial signal

NCT05142722 · Phase 3 · completed

Participants were randomized 2:1 to obicetrapib or placebo and the trial was quadruple-blinded, with 2,530 participants enrolled. The primary LDL-cholesterol endpoint was met, with a statistically significant treatment difference, but LDL cholesterol is a surrogate laboratory endpoint rather than a hard clinical or endoscopic measure, supporting a moderate grade.

Next expected readout: November 2026 · NCT06496243 (registry estimate)

Reported efficacy

Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571) (met)

Result source: NCT05142722

Obicetrapib/ezetimibe (Evlarco)

Marketed by A. Menarini under a licence from NewAmsterdam Pharma

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
Partial signal

NCT06005597 · Phase 3 · completed

The study was randomized, quadruple-blind, and placebo- and active-controlled, with 407 participants distributed across four treatment groups. All four prespecified LDL-C comparisons significantly favored the obicetrapib-containing treatment, but LDL-C is a laboratory surrogate rather than a hard clinical endpoint, so the evidence is rated moderate.

Reported efficacy

Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days); Effect of Fixed Dose Combination (FDC) Compared to Ezetimibe Monotherapy on LDL-C (84 Days); Effect of Fixed Dose Combination (FDC) Compared to Obicetrapib Monotherapy on LDL-C (84 Days); Effect of Obicetrapib Monotherapy Compared to Placebo on LDL-C (84 Days): Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564) (met)

Result source: NCT06005597

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointObicetrapibObicetrapib/​ezetimibe (Evlarco)
LDL-C, % change-29.9% vs 2.7%−32.6 vs placebo10mg · wk 12 · n 1679NCT05142722
68 other results
  • -36.0% vs 0.3% 10 mg · wk 12 · n 232 · Phase 3 · primary NCT05425745
  • -45.6% vs 3.0% wk 12 · n 102 · Phase 3 · primary NCT06005597
  • -28.8% vs 3.0% wk 12 · n 102 · Phase 3 · primary NCT06005597
  • -45.6% vs -17.6% wk 12 · n 102 · Phase 3 · primary NCT06005597
  • -25.3% vs -1.3% 10mg · wk 52.142857142857146 · n 1679 · Phase 3 · secondary NCT05142722
  • -29.1% vs 4.7% 10mg · wk 25.714285714285715 · n 1685 · Phase 3 · secondary NCT05142722
  • -31.1% vs 10.3% 10 mg · wk 52 · n 232 · Phase 3 · secondary NCT05425745
  • -31.8% vs 6.0% 10 mg · wk 26 · n 234 · Phase 3 · secondary NCT05425745
  • -36.8% vs -0.8% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -45.8% vs -0.9% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -36.6% vs -0.5% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -36.3% vs 0.4% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -43.7% vs 0.7% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -36.1% vs 0.7% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -43.4% vs -5.5% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -45.6% vs 0% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -44.2% vs -5% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -46.1% vs -7.1% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -50.8% vs -6.5% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -46.8% vs -6.7% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -33.8% vs -0.8% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -31.9% vs -0.9% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -33.8% vs -0.5% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -30.5% vs 0.4% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -30.4% vs 0.7% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -30.5% vs 0.7% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -38.0% vs -5.5% 5 mg · wk 8 · n 39 · Phase 2 · primary NCT04753606
  • -42.9% vs 0% 5 mg · wk 8 · n 39 · Phase 2 · primary NCT04753606
  • -38.0% vs -5% 5 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -36.0% vs -7.1% 5 mg · wk 8 · n 38 · Phase 2 · primary NCT04753606
  • -41.5% vs -6.5% 5 mg · wk 8 · n 38 · Phase 2 · primary NCT04753606
  • -35.6% vs -6.7% 5 mg · wk 8 · n 38 · Phase 2 · primary NCT04753606
  • -25.9% vs -0.8% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -24.8% vs -0.9% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.3% vs -0.5% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.1% vs 0.4% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.0% vs 0.7% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.5% vs 0.7% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -59.1% vs -0.8% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -63.4% vs -6.3% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -59.2% vs -0.8% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -59.5% vs -1.5% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -62.8% vs -4.0% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -59.7% vs -1.5% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -45.6% vs -0.2% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -52.0% vs -1.4% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -43.5% vs 1.4% wk 8 · n 27 · Phase 2 · primary NCT04770389
  • -44.4% vs -1.5% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -51.4% vs -2% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -44.1% vs -0.8% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -39.4% vs -0.8% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -43.5% vs -6.3% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -39.2% vs -0.8% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -39.0% vs -1.5% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -43.5% vs -4.0% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -38.8% vs -1.5% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -31.9% vs -0.2% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -34.4% vs -1.4% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -32.0% vs 1.4% wk 8 · n 28 · Phase 2 · secondary NCT04770389
  • -27.9% vs -1.5% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -30.1% vs -2% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -29.0% vs -0.8% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -45.6% vs -12.7% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -52.0% vs -14.8% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -43.5% vs -13.4% wk 8 · n 27 · Phase 2 · secondary NCT04770389
  • -31.9% vs -12.7% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -34.4% vs -14.8% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -32.0% vs -13.4% wk 8 · n 28 · Phase 2 · secondary NCT04770389
—Not reported
Non-HDL-C, % change-22.4% vs 0.6%−23 vs placebo10mg · wk 52.142857142857146 · n 1685NCT05142722
23 other results
  • -24.6% vs 3.7% 10mg · wk 25.714285714285715 · n 1685 · Phase 3 · secondary NCT05142722
  • -26.6% vs 2.8% 10mg · wk 12 · n 1685 · Phase 3 · secondary NCT05142722
  • -25.8% vs 11.6% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT05425745
  • -27.1% vs 5.9% 10 mg · wk 26 · n 234 · Phase 3 · secondary NCT05425745
  • -31.6% vs 2.8% 10 mg · wk 12 · n 234 · Phase 3 · secondary NCT05425745
  • -42.4% vs 2.7% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -27.2% vs 2.7% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -42.4% vs -17.0% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -30.3% vs -1.8% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -37.0% vs -0.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -30.3% vs -1.7% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -39.3% vs -4.2% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -44.4% vs -3.5% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -39.9% vs -3.8% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -30.4% vs -1.8% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -29.8% vs -0.4% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -30.1% vs -1.7% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -34.3% vs -4.2% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -38.9% vs -3.5% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -34.4% vs -3.8% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -25.4% vs -1.8% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -23.7% vs -0.4% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -25.7% vs -1.7% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
—Not reported
ApoB, % change-15.6% vs -1.8%−13.8 vs placebo10mg · wk 52.142857142857146 · n 1685NCT05142722
38 other results
  • -16.1% vs 2.2% 10mg · wk 25.714285714285715 · n 1685 · Phase 3 · secondary NCT05142722
  • -17.8% vs 1.1% 10mg · wk 12 · n 1685 · Phase 3 · secondary NCT05142722
  • -17.6% vs 8.2% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT05425745
  • -18.3% vs 6.0% 10 mg · wk 26 · n 234 · Phase 3 · secondary NCT05425745
  • -21.4% vs 2.9% 10 mg · wk 12 · n 234 · Phase 3 · secondary NCT05425745
  • -26.9% vs 2.3% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -17.5% vs 2.3% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -26.9% vs -12.7% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -21.7% vs 0.5% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -24.2% vs -2.0% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -21.6% vs 0.7% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -26.7% vs -1.2% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -29.7% vs -0.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -26.3% vs -1.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -27.2% vs -4.7% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -29.8% vs -2.6% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -28.1% vs -4.1% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -24.5% vs -1.2% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -21.4% vs -0.4% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -23.9% vs -1.4% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -22.6% vs -4.7% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -24.4% vs -2.6% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -22.4% vs -4.1% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -19.8% vs -1.2% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -22.5% vs -0.4% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -20.4% vs -1.4% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -34.7% vs 0.5% wk 12 · n 31 · Phase 2 · secondary NCT05266586
  • -34.4% vs -2.0% wk 12 · n 31 · Phase 2 · secondary NCT05266586
  • -35.0% vs 0.7% wk 12 · n 31 · Phase 2 · secondary NCT05266586
  • -31.6% vs -1.2% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -34.8% vs -0.9% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -29.7% vs -0.1% wk 8 · n 27 · Phase 2 · secondary NCT04770389
  • -22.1% vs -1.2% wk 8 · n 26 · Phase 2 · secondary NCT04770389
  • -23.5% vs -0.9% wk 8 · n 26 · Phase 2 · secondary NCT04770389
  • -22.5% vs -0.1% wk 8 · n 28 · Phase 2 · secondary NCT04770389
  • -31.6% vs -8.8% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -34.8% vs -8.9% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -29.7% vs -8.9% wk 8 · n 27 · Phase 2 · secondary NCT04770389
—Not reported
Lp(a), % change-0.5% vs 13.7%−14.1 vs placebo10mg · wk 12 · n 1685NCT05142722
3 other results
  • -32.3% vs -0.9% 10mg · wk 12 · n 1685 · Phase 3 · secondary NCT05142722
  • -29.9% vs 24.4% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT05425745
  • -35.4% vs 10.5% 10 mg · wk 12 · n 234 · Phase 3 · secondary NCT05425745
—Not reported
3-point MACE (% with event)—Trial running · NCT05202509—Not reported

LDL-C, % change

Obicetrapib
-29.9% vs 2.7%−32.6 vs placebo10mg · wk 12 · n 1679NCT05142722
68 other results
  • -36.0% vs 0.3% 10 mg · wk 12 · n 232 · Phase 3 · primary NCT05425745
  • -45.6% vs 3.0% wk 12 · n 102 · Phase 3 · primary NCT06005597
  • -28.8% vs 3.0% wk 12 · n 102 · Phase 3 · primary NCT06005597
  • -45.6% vs -17.6% wk 12 · n 102 · Phase 3 · primary NCT06005597
  • -25.3% vs -1.3% 10mg · wk 52.142857142857146 · n 1679 · Phase 3 · secondary NCT05142722
  • -29.1% vs 4.7% 10mg · wk 25.714285714285715 · n 1685 · Phase 3 · secondary NCT05142722
  • -31.1% vs 10.3% 10 mg · wk 52 · n 232 · Phase 3 · secondary NCT05425745
  • -31.8% vs 6.0% 10 mg · wk 26 · n 234 · Phase 3 · secondary NCT05425745
  • -36.8% vs -0.8% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -45.8% vs -0.9% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -36.6% vs -0.5% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -36.3% vs 0.4% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -43.7% vs 0.7% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -36.1% vs 0.7% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -43.4% vs -5.5% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -45.6% vs 0% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -44.2% vs -5% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -46.1% vs -7.1% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -50.8% vs -6.5% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -46.8% vs -6.7% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -33.8% vs -0.8% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -31.9% vs -0.9% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -33.8% vs -0.5% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -30.5% vs 0.4% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -30.4% vs 0.7% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -30.5% vs 0.7% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -38.0% vs -5.5% 5 mg · wk 8 · n 39 · Phase 2 · primary NCT04753606
  • -42.9% vs 0% 5 mg · wk 8 · n 39 · Phase 2 · primary NCT04753606
  • -38.0% vs -5% 5 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -36.0% vs -7.1% 5 mg · wk 8 · n 38 · Phase 2 · primary NCT04753606
  • -41.5% vs -6.5% 5 mg · wk 8 · n 38 · Phase 2 · primary NCT04753606
  • -35.6% vs -6.7% 5 mg · wk 8 · n 38 · Phase 2 · primary NCT04753606
  • -25.9% vs -0.8% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -24.8% vs -0.9% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.3% vs -0.5% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.1% vs 0.4% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.0% vs 0.7% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.5% vs 0.7% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -59.1% vs -0.8% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -63.4% vs -6.3% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -59.2% vs -0.8% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -59.5% vs -1.5% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -62.8% vs -4.0% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -59.7% vs -1.5% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -45.6% vs -0.2% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -52.0% vs -1.4% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -43.5% vs 1.4% wk 8 · n 27 · Phase 2 · primary NCT04770389
  • -44.4% vs -1.5% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -51.4% vs -2% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -44.1% vs -0.8% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -39.4% vs -0.8% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -43.5% vs -6.3% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -39.2% vs -0.8% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -39.0% vs -1.5% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -43.5% vs -4.0% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -38.8% vs -1.5% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -31.9% vs -0.2% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -34.4% vs -1.4% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -32.0% vs 1.4% wk 8 · n 28 · Phase 2 · secondary NCT04770389
  • -27.9% vs -1.5% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -30.1% vs -2% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -29.0% vs -0.8% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -45.6% vs -12.7% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -52.0% vs -14.8% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -43.5% vs -13.4% wk 8 · n 27 · Phase 2 · secondary NCT04770389
  • -31.9% vs -12.7% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -34.4% vs -14.8% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -32.0% vs -13.4% wk 8 · n 28 · Phase 2 · secondary NCT04770389
Obicetrapib/​ezetimibe (Evlarco)
—Not reported

Non-HDL-C, % change

Obicetrapib
-22.4% vs 0.6%−23 vs placebo10mg · wk 52.142857142857146 · n 1685NCT05142722
23 other results
  • -24.6% vs 3.7% 10mg · wk 25.714285714285715 · n 1685 · Phase 3 · secondary NCT05142722
  • -26.6% vs 2.8% 10mg · wk 12 · n 1685 · Phase 3 · secondary NCT05142722
  • -25.8% vs 11.6% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT05425745
  • -27.1% vs 5.9% 10 mg · wk 26 · n 234 · Phase 3 · secondary NCT05425745
  • -31.6% vs 2.8% 10 mg · wk 12 · n 234 · Phase 3 · secondary NCT05425745
  • -42.4% vs 2.7% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -27.2% vs 2.7% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -42.4% vs -17.0% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -30.3% vs -1.8% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -37.0% vs -0.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -30.3% vs -1.7% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -39.3% vs -4.2% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -44.4% vs -3.5% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -39.9% vs -3.8% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -30.4% vs -1.8% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -29.8% vs -0.4% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -30.1% vs -1.7% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -34.3% vs -4.2% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -38.9% vs -3.5% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -34.4% vs -3.8% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -25.4% vs -1.8% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -23.7% vs -0.4% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -25.7% vs -1.7% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
Obicetrapib/​ezetimibe (Evlarco)
—Not reported

ApoB, % change

Obicetrapib
-15.6% vs -1.8%−13.8 vs placebo10mg · wk 52.142857142857146 · n 1685NCT05142722
38 other results
  • -16.1% vs 2.2% 10mg · wk 25.714285714285715 · n 1685 · Phase 3 · secondary NCT05142722
  • -17.8% vs 1.1% 10mg · wk 12 · n 1685 · Phase 3 · secondary NCT05142722
  • -17.6% vs 8.2% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT05425745
  • -18.3% vs 6.0% 10 mg · wk 26 · n 234 · Phase 3 · secondary NCT05425745
  • -21.4% vs 2.9% 10 mg · wk 12 · n 234 · Phase 3 · secondary NCT05425745
  • -26.9% vs 2.3% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -17.5% vs 2.3% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -26.9% vs -12.7% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -21.7% vs 0.5% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -24.2% vs -2.0% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -21.6% vs 0.7% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -26.7% vs -1.2% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -29.7% vs -0.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -26.3% vs -1.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -27.2% vs -4.7% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -29.8% vs -2.6% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -28.1% vs -4.1% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -24.5% vs -1.2% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -21.4% vs -0.4% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -23.9% vs -1.4% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -22.6% vs -4.7% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -24.4% vs -2.6% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -22.4% vs -4.1% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -19.8% vs -1.2% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -22.5% vs -0.4% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -20.4% vs -1.4% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -34.7% vs 0.5% wk 12 · n 31 · Phase 2 · secondary NCT05266586
  • -34.4% vs -2.0% wk 12 · n 31 · Phase 2 · secondary NCT05266586
  • -35.0% vs 0.7% wk 12 · n 31 · Phase 2 · secondary NCT05266586
  • -31.6% vs -1.2% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -34.8% vs -0.9% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -29.7% vs -0.1% wk 8 · n 27 · Phase 2 · secondary NCT04770389
  • -22.1% vs -1.2% wk 8 · n 26 · Phase 2 · secondary NCT04770389
  • -23.5% vs -0.9% wk 8 · n 26 · Phase 2 · secondary NCT04770389
  • -22.5% vs -0.1% wk 8 · n 28 · Phase 2 · secondary NCT04770389
  • -31.6% vs -8.8% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -34.8% vs -8.9% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -29.7% vs -8.9% wk 8 · n 27 · Phase 2 · secondary NCT04770389
Obicetrapib/​ezetimibe (Evlarco)
—Not reported

Lp(a), % change

Obicetrapib
-0.5% vs 13.7%−14.1 vs placebo10mg · wk 12 · n 1685NCT05142722
3 other results
  • -32.3% vs -0.9% 10mg · wk 12 · n 1685 · Phase 3 · secondary NCT05142722
  • -29.9% vs 24.4% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT05425745
  • -35.4% vs 10.5% 10 mg · wk 12 · n 234 · Phase 3 · secondary NCT05425745
Obicetrapib/​ezetimibe (Evlarco)
—Not reported

3-point MACE (% with event)

Obicetrapib
—Trial running · NCT05202509
Obicetrapib/​ezetimibe (Evlarco)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Obicetrapib/ezetimibe (Evlarco)
Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564) NCT06005597 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Obicetrapib: 4 of 4 rows · Obicetrapib/ezetimibe (Evlarco): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricObicetrapib
Dropout rate
5.1%10mga
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 12 more results
4.2%10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2%Fixed Dose Combination
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
2.9%Monotherapy Obicetrapib
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0%10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
0%2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
7.7%10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
5%Combination Therapy
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
0%10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
18.5%Combination Therapy
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
7.1%Obicetrapib Monotherapy
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
Discontinued due to AEs
0.1%10mga
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 12 more results
0.4%10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Fixed Dose Combination
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—Monotherapy Obicetrapib
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
—5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
5.1%10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
2.5%Combination Therapy
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
0%10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
7.4%Combination Therapy
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
0%Obicetrapib Monotherapy
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
Serious AEs
12.5%10mga
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 12 more results
5.6%10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.9%Fixed Dose Combination
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
5.9%Monotherapy Obicetrapib
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0%10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
4%5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
0%2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
2.6%10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
0%Combination Therapy
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
0%10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
0%Combination Therapy
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
0%Obicetrapib Monotherapy
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
Most frequent reported AEs
10mga
hypertension 4.9% (placebo 3.9%)
covid-19 4.8% (placebo 5.7%)
upper respiratory tract infection 2.9% (placebo 3.9%)
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 12 more results
10 mg
influenza 9% (placebo 5.9%)
covid-19 6.4% (placebo 6.8%)
nasopharyngitis 6.4% (placebo 4.2%)
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
diarrhoea 4.9% (placebo 0%)
covid-19 3.9% (placebo 1%)
fatigue 3.9% (placebo 1%)
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
hypertension 8.8% (placebo 2.9%)
arthralgia 6.9% (placebo 2.9%)
headache 5.9% (placebo 2%)
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
10 mg
back pain 7.7% (placebo 11.5%)
nasopharyngitis 7.7% (placebo 11.5%)
rhinitis allergic 7.7% (placebo 0%)
NCT05421078 · Phase 2 · registry result, not featured evidence
5 mg
blood glucose increased 4% (placebo 0%)
blood pressure increased 4% (placebo 0%)
chest pain 4% (placebo 0%)
NCT05421078 · Phase 2 · registry result, not featured evidence
2.5 mg
diabetes mellitus 8% (placebo 0%)
hypoglycaemia 8% (placebo 0%)
abdominal distension 4% (placebo 0%)
NCT05421078 · Phase 2 · registry result, not featured evidence
10 mg
abdominal pain 2.6% (placebo 0%)
abdominal pain upper 2.6% (placebo 0%)
acute myocardial infarction 2.6% (placebo 0%)
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
nausea 5% (placebo 5%)
arthralgia 2.5% (placebo 2.5%)
bronchitis 2.5% (placebo 0%)
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
10 mg
arthralgia 2.5% (placebo 2.5%)
arthropod sting 2.5% (placebo 0%)
cardiomegaly 2.5% (placebo 0%)
NCT04753606 · Phase 2 · registry result, not featured evidence
5 mg
fatigue 5% (placebo 5%)
hypertension 5% (placebo 0%)
type 2 diabetes mellitus 5% (placebo 0%)
NCT04753606 · Phase 2 · registry result, not featured evidence
diarrhoea 7.4% (placebo 0%)
abdominal pain 3.7% (placebo 0%)
back pain 3.7% (placebo 0%)
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
covid-19 3.6% (placebo 0%)
flatulence 3.6% (placebo 0%)
onychomycosis 3.6% (placebo 0%)
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 9 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Obicetrapib

LDL-C -29.94% (n=1679) vs 2.7% (n=842) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 68 more results
-29.09% (n=1685) vs 4.68% (n=843) placebo @ 25.714285714285715wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-25.25% (n=1679) vs -1.27% (n=842) placebo @ 52.142857142857146wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-36.05% (n=232) vs 0.25% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-31.8% (n=234) vs 5.98% (n=118) placebo @ 26wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-31.14% (n=232) vs 10.3% (n=118) placebo @ 52wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-36.8% (n=26) vs -0.78% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-45.8% (n=26) vs -0.89% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-36.6% (n=26) vs -0.48% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-36.29% (n=26) vs 0.43% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-43.72% (n=26) vs 0.67% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-36.12% (n=26) vs 0.69% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-39.35% (n=26) vs -0.83% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-43.5% (n=26) vs -6.35% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-39.2% (n=26) vs -0.85% (n=40) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-39.04% (n=26) vs -1.49% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-43.55% (n=26) vs -3.95% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-38.75% (n=26) vs -1.54% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-43.35% (n=40) vs -5.48% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-45.65% (n=40) vs 0% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-44.18% (n=40) vs -5% (n=40) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-46.06% (n=40) vs -7.11% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-50.75% (n=40) vs -6.5% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-46.77% (n=40) vs -6.7% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-33.78% (n=25) vs -0.78% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-31.94% (n=25) vs -0.89% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-33.82% (n=25) vs -0.48% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-30.5% (n=25) vs 0.43% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-30.4% (n=25) vs 0.67% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-30.54% (n=25) vs 0.69% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-37.97% (n=39) vs -5.48% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-42.9% (n=39) vs 0% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-37.97% (n=40) vs -5% (n=40) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-35.98% (n=38) vs -7.11% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-41.45% (n=38) vs -6.5% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-35.65% (n=38) vs -6.7% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-25.9% (n=25) vs -0.78% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-24.81% (n=25) vs -0.89% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-26.32% (n=25) vs -0.48% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-26.1% (n=25) vs 0.43% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-25.97% (n=25) vs 0.67% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-26.51% (n=25) vs 0.69% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-45.58% (n=102) vs 3.03% (n=100) placebo @ 12wk
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-45.58% (n=102) vs -17.63% (n=101) Ezetimibe @ 12wk
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-28.82% (n=102) vs 3.03% (n=100) placebo @ 12wk
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-59.07% (n=31) vs -0.83% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-63.4% (n=31) vs -6.35% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-59.23% (n=31) vs -0.85% (n=40) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-59.51% (n=31) vs -1.49% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-62.8% (n=31) vs -3.95% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-59.69% (n=31) vs -1.54% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-45.63% (n=24) vs -0.17% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-51.95% (n=24) vs -1.4% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-43.55% (n=27) vs 1.37% (n=28) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-44.38% (n=24) vs -1.53% (n=22) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-51.4% (n=24) vs -2% (n=22) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-44.1% (n=24) vs -0.78% (n=22) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-31.88% (n=25) vs -0.17% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-34.4% (n=25) vs -1.4% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-31.99% (n=28) vs 1.37% (n=28) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-27.94% (n=25) vs -1.53% (n=22) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-30.1% (n=25) vs -2% (n=22) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-28.98% (n=25) vs -0.78% (n=22) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-45.63% (n=24) vs -12.69% (n=25) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-51.95% (n=24) vs -14.8% (n=25) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-43.55% (n=27) vs -13.42% (n=28) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-31.88% (n=25) vs -12.69% (n=25) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-34.4% (n=25) vs -14.8% (n=25) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-31.99% (n=28) vs -13.42% (n=28) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
Apo B -17.84% (n=1685) vs 1.08% (n=843) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 38 more results
-16.07% (n=1685) vs 2.23% (n=843) placebo @ 25.714285714285715wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-15.57% (n=1685) vs -1.77% (n=843) placebo @ 52.142857142857146wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-21.45% (n=234) vs 2.93% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-18.3% (n=234) vs 6.02% (n=118) placebo @ 26wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-17.62% (n=234) vs 8.15% (n=118) placebo @ 52wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-26.66% (n=26) vs -1.23% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-29.67% (n=26) vs -0.36% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-26.29% (n=26) vs -1.42% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-21.73% (n=26) vs 0.51% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-24.2% (n=26) vs -2.05% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-21.56% (n=26) vs 0.72% (n=40) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-27.19% (n=40) vs -4.67% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-29.75% (n=40) vs -2.6% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-28.12% (n=40) vs -4.13% (n=40) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-24.48% (n=25) vs -1.23% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-21.43% (n=25) vs -0.36% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-23.87% (n=25) vs -1.42% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-22.62% (n=39) vs -4.67% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-24.4% (n=39) vs -2.6% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-22.4% (n=40) vs -4.13% (n=40) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-19.8% (n=25) vs -1.23% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-22.5% (n=25) vs -0.36% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-20.43% (n=25) vs -1.42% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-26.91% (n=102) vs 2.28% (n=102) placebo @ 12wk
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-17.5% (n=102) vs 2.28% (n=102) placebo @ 12wk
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-26.91% (n=102) vs -12.71% (n=101) Ezetimibe @ 12wk
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-34.66% (n=31) vs 0.51% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-34.4% (n=31) vs -2.05% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-34.95% (n=31) vs 0.72% (n=40) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-31.62% (n=24) vs -1.17% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-34.75% (n=24) vs -0.9% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-29.73% (n=27) vs -0.11% (n=28) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-22.15% (n=26) vs -1.17% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-23.5% (n=26) vs -0.9% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-22.46% (n=28) vs -0.11% (n=28) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-31.62% (n=24) vs -8.78% (n=25) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-34.75% (n=24) vs -8.9% (n=25) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-29.73% (n=27) vs -8.92% (n=28) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
Non-HDL-C -26.64% (n=1685) vs 2.81% (n=843) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 23 more results
-24.63% (n=1685) vs 3.68% (n=843) placebo @ 25.714285714285715wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-22.38% (n=1685) vs 0.63% (n=843) placebo @ 52.142857142857146wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-31.62% (n=234) vs 2.83% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-27.08% (n=234) vs 5.92% (n=118) placebo @ 26wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-25.84% (n=234) vs 11.64% (n=118) placebo @ 52wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-30.25% (n=26) vs -1.8% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-36.96% (n=26) vs -0.37% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-30.28% (n=26) vs -1.72% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-39.25% (n=40) vs -4.22% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-44.4% (n=40) vs -3.5% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-39.86% (n=40) vs -3.83% (n=40) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-30.38% (n=25) vs -1.8% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-29.82% (n=25) vs -0.37% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-30.11% (n=25) vs -1.72% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-34.28% (n=39) vs -4.22% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-38.9% (n=39) vs -3.5% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-34.37% (n=40) vs -3.83% (n=40) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-25.42% (n=25) vs -1.8% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-23.74% (n=25) vs -0.37% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-25.66% (n=25) vs -1.72% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-42.42% (n=102) vs 2.71% (n=102) placebo @ 12wk
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-27.19% (n=102) vs 2.71% (n=102) placebo @ 12wk
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-42.42% (n=102) vs -16.98% (n=101) Ezetimibe @ 12wk
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
HDL-C 136.87% (n=1685) vs 0.61% (n=843) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 20 more results
135.61% (n=1685) vs 1.18% (n=843) placebo @ 25.714285714285715wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
125.4% (n=1685) vs 3.36% (n=843) placebo @ 52.142857142857146wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
139.92% (n=234) vs 1.26% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
133.83% (n=234) vs 2.63% (n=118) placebo @ 26wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
127.67% (n=234) vs 6.28% (n=118) placebo @ 52wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
158.75% (n=26) vs 5.57% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
158.9% (n=26) vs 5.22% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
159.87% (n=26) vs 3.9% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
156.41% (n=40) vs -6.62% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
164.95% (n=40) vs -4.9% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
157.35% (n=40) vs -6.98% (n=40) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
153.16% (n=25) vs 5.57% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
144.44% (n=25) vs 5.22% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
151.3% (n=25) vs 3.9% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
123.92% (n=39) vs -6.62% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
135.4% (n=39) vs -4.9% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
122.29% (n=40) vs -6.98% (n=40) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
134.75% (n=25) vs 5.57% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
114.29% (n=25) vs 5.22% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
137% (n=25) vs 3.9% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
Lp(a -0.48% (n=1685) vs 13.65% (n=843) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 3 more results
-32.3% (n=1685) vs -0.9% (n=843) placebo @ 12wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-35.42% (n=234) vs 10.52% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-29.93% (n=234) vs 24.37% (n=118) placebo @ 52wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Apo A1 43.44% (n=1685) vs 0.26% (n=843) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Total Cholesterol 17.66% (n=1685) vs -0.02% (n=843) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 5 more results
18.68% (n=1685) vs 0.85% (n=843) placebo @ 25.714285714285715wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
17.96% (n=1685) vs -0.58% (n=843) placebo @ 52.142857142857146wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
12.09% (n=234) vs 2.34% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
14.43% (n=234) vs 4.44% (n=118) placebo @ 26wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
13.92% (n=234) vs 9.32% (n=118) placebo @ 52wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Triglycerides -0.17% (n=1685) vs 7.66% (n=843) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 5 more results
0.25% (n=1685) vs 8.22% (n=843) placebo @ 25.714285714285715wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0.6% (n=1685) vs 6.33% (n=843) placebo @ 52.142857142857146wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-1.57% (n=234) vs 10.16% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
4.49% (n=234) vs 12.43% (n=118) placebo @ 26wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.27% (n=234) vs 7.39% (n=118) placebo @ 52wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C -45.58% (n=102) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
-28.82% (n=102) @ 12wk
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Non-HDL-C -42.42% (n=102) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
-27.19% (n=102) @ 12wk
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Apo B -26.91% (n=102) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
-17.5% (n=102) @ 12wk
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Obicetrapib's landscape · Obicetrapib/ezetimibe (Evlarco)'s landscape